8/18/25 1:30-3:00pm Zoom Virtual Meeting

# Institutional Biosafety Committee Meeting minutes

# Meeting Attendance:

- Members in attendance:
  - o Elena Demireva
  - Jonathan Hardy
  - o Dave Morgan
  - o Guo-Qing Song
  - o Raj Kulkarni
  - o Michael Bachmann
  - Sarah Roosa
- Members not in attendance:
  - o Jamie Willard-Smith
  - o Andras Komaromy
  - o Carrie Anglewicz
  - o Jan Patterson Samson
  - Carolina de Aguiar Ferreira
  - o Simon Petersen-Jones
- Others in attendance:
  - o Chris Colvin
  - Alessandra Hunt
  - o Luis Ochoa Carrera

# Call to order:

Elena Demireva

#### Roll call:

Chris Colvin

# Discussion of the agenda:

• Approved as written.

#### Discussion of minutes:

• Approved as written.

8/18/25 1:30-3:00pm Zoom Virtual Meeting

# Registration review:

Study Info

#### Safety00011010: ■

Mechanisms of TGF-β family regulation Training: Complete for all members listed NIH III E-1, RG-1, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
  - o 3a: Add other cells if used to receive rDNA inserts.
  - 4a: Include all cells that are listed in the recipient's section that will receive rDNA.
  - o 4b: Include pMK vectors mentioned in earlier sections
  - o 5a. Yes and list E.coli has host
- rDNA Work Description
  - o 2: Remove E. coli from recipients.
- Exposure Assessment
  - o 1: Remove statement "probably none". Expand on the potential of Bloodborne pathogens with the use of human cell lines.
  - o 2: What is the use of respirators for?
  - o 3: Update eye wash flush date.

#### Study Info

#### Safety0001276:

Genetic regulation of cell fate in mouse embryo and stem cells

Training: Complete for all members listed

NIH III D, RG-2, BSL-2+

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - o 2: Typo in the word "titrated".
  - o 2: Add information for the ZIKV experiments if they are still on going. If just storing the virus can leave as is.
- Virus
  - The IBC recommends switching from a 2<sup>nd</sup> generation to 3<sup>rd</sup> generation or later lentivirus for increased biosafety for future experiments.
- rDNA usage
  - o 3b: Add Cas9 and Cre biological activity and source.
- rDNA Work Description
  - 4: Change to Yes for VSV pseudotyping.

8/18/25 1:30-3:00pm Zoom Virtual Meeting

- o 5: This only discusses MMLV, if using other viruses include information.
- o 6: Remove first sentence that begins with "Human 293T.....". List genus, species and strain of pathogens
- Exposure Assessment
  - o 1. and 6. Discuss exposure risk to pregnant personnel.

#### Study Info

#### Safety0001282: ■

**Expression of NOR and N2OR** 

**Training: Complete for all members listed** 

NIH III E, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
  - o 5: Remove P. stutzeri as a host.
- rDNA Work Description
  - o 2: Remove E. coli from recipients.

### Study Info

#### Safety0001289:

Stem Cell Core: iPSC Reprogramming
Training: Complete for all members listed

NIH III D, RG-2, BSL-2

This registration has been approved as is. Elena Demireva has abstained from the vote.

### Study Info

#### Safety0001290:

**Metabolism Genomics 2025** 

**Training: Complete for all members listed** 

NIH III E-2-aRG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA usage
  - o 4a: Include the use of plasmids and TRV as vectors.
  - o 5a: Typo on strain "GV3101".
- Exposure Assessment
  - o 1: Comment on if transgenic plants are released.

8/18/25 1:30-3:00pm Zoom Virtual Meeting

#### Study Info

Safety0001295:

- Gene Transfer 2025

**Training:** Complete for all members listed

NIH III D-4, RG-2, BSL-2

This registration has been approved as is. Sarah Roosa has abstained from the vote.

### Study Info

### Safety0001303:

Telomerase catalysis and its recruitment to telomeres

**Training: Complete for all members listed** 

NIH III D-3, RG-2, BSL-2+

This registration has been approved with edits. The PI has been asked to clarify the following:

- Virus
  - o Retrovirus MMLV is BSL-2
  - The IBC recommends switching from a 2<sup>nd</sup> generation to 3<sup>rd</sup> generation or later lentivirus for increased biosafety for future experiments.
- rDNA Usage
  - o 5a: Only E. coli, 293 and SF9 cells are hosts, remove the rest.
  - o 8: Comment on risks of TERT insert expression as an oncogene
  - o Add a detailed exposure protocol or refer to an SOP.
- rDNA Work Description
  - o 2: Remove bacterial strains as recipients.
  - o 4: Change to Yes
  - o 6: Change to Yes
  - o 7a: Expand on experimental goals.
- Exposure Assessment
  - 1: Remove wording "in general the human cell lines we use are not harmful". Comment on Bloodborne Pathogen risks associated with human cell line work.
- Supporting documents
  - o Needs sharps evaluation form.

### Study Info

**Safety0001304:** 

-gene editing to study immunogenic processes

Training: Complete for all members listed

NIH III D-1-a, RG-2, BSL-2+

8/18/25 1:30-3:00pm Zoom Virtual Meeting

This registration has been approved with edits. The PI has been asked to clarify the following:

- Biosafety Summary
  - 2: Clarify if putting rDNA into animals, if so update NIH category to NIH III-D-4.
- Virus
  - The IBC recommends switching from a 2<sup>nd</sup> generation Lentivirus to 3<sup>rd</sup> generation or later for safety purposes.
- rDNA Usage
  - 4e: Remove statement "No other features", check on and add additional safety features e.g. 3' LTR deletions and self- inactivation of the virus.
  - o 5a: Leave HEK, Phoenix and E. coli, remove the others as they are recipients.
  - 9: Include full response procedure or refer to an SOP. You will seek help from Lansing Urgent care, not reporting to the MSU occupational health department.
- rDNA Work Description
  - 4: Change to Yes for VSV pseudotyping.
- Exposure Assessment
  - 4: IBC recommends switching to plastic pipettes with use of 2<sup>nd</sup> generation Lentivirus and phasing out glass pasteur pipettes long term for use with human cell line or infectious materials.
- Supporting Documents
  - o Include sharps evaluation form.

### Study Info

### Safety0001305: |

cellulose synthesis in cotton

**Training: Complete for all members listed** 

NIH III E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- Basic Summary
  - o 3: Remove floral dipping as transformation method.
- rDNA Usage
  - o 5a: Only E. coli is a host, remove the rest.
- rDNA Work Description
  - o 2: Remove E. coli as a recipient, leave the rest.

#### Study Info

Safety0001306: |

cellulose synthase

**Training: Complete for all members listed** 

8/18/25 1:30-3:00pm Zoom Virtual Meeting

#### NIH III E-2-a, RG-1, BSL-1

This registration has been approved with edits. The PI has been asked to clarify the following:

- rDNA Usage
  - o 3b: Add biological activity for CESA inserts
  - o 4b: Add pCR8 and pCambia1301 vectors,
- rDNA Work Description
  - o 2: If Arabidopsis is a recipient leave, otherwise remove.
- Exposure Assessment
  - o 3. update eye wash flush date
- Transgenic Plants
  - o This section is needed only if creating stable transgenic plants, can be omitted if doing only transient expression experiment

#### Study Info

#### Safety0001309:

Contrast agent transporter development 2025 Training: Complete for all members listed

NIH III D-3, RG-2, BSL-2

This registration has been approved with edits. Elena Demireva has abstained from the vote. The PI has been asked to clarify the following:

- Team members
  - o Update Team, remove people no longer working on this project.
- Cells
  - 5e: Update flow addendum, answer all the questions correctly, origin from humans missing.
- Supporting Documents
  - Update Sharps forms to include sharps used with human material and infectious materials. Plastic serological pipettes no longer considered sharps.

### Study Info

### Safety0001323: I

Genetic studies of Caulobacter and Brucella spp.

Training: Complete for all members listed

NIH III D-1-a, RG-2, BSL-2

This registration has been approved with edits. The PI has been asked to clarify the following:

- Bacteria
  - o 2: Typo on "lineage".
- Cells
  - o 5e: Update to new flow addendum form.

8/18/25 1:30-3:00pm Zoom Virtual Meeting

- rDNA usage
  - o 5a: Remove Caulobacter and Brucella if only recipients.
- rDNA Work Description
  - o 2: Remove E. coli, add Bacteriodes.

## New Items:

• CLICK upgrade complete. Training records are now appearing for team members.

### **Previous Submissions:**

- Safety0001223
  Safety0001206
  Safety0001281
  Safety0001245
  Safety0001272
  Safety0001271
  Safety0001265
- Safety0001269

# Next Meeting:

September 8, 2025 1:30 pm via zoom